GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Altman Z-Score
中文

Adynxx (Adynxx) Altman Z-Score

: N/A (As of Today)
View and export this data going back to 1998. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Adynxx has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Adynxx's Altman Z-Score or its related term are showing as below:


Adynxx Altman Z-Score Historical Data

The historical data trend for Adynxx's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.81 -1.09 -4.47 -7.13 -20.16

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.53 -20.16 -19.85 -32.98 -29.98

Competitive Comparison

For the Biotechnology subindustry, Adynxx's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx Altman Z-Score Distribution

For the Biotechnology industry and Healthcare sector, Adynxx's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Adynxx's Altman Z-Score falls into.



Adynxx Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Adynxx's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-3.4582+1.4*-14.2323+3.3*-1.9536+0.6*0+1.0*0.181
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2019:
Total Assets was $3.25 Mil.
Total Current Assets was $2.54 Mil.
Total Current Liabilities was $13.80 Mil.
Retained Earnings was $-46.31 Mil.
Pre-Tax Income was -1.895 + -4.618 + -1.106 + -1.334 = $-8.95 Mil.
Interest Expense was -0.223 + -2.373 + 0 + 0 = $-2.60 Mil.
Revenue was 0 + 0 + 0.129 + 0.46 = $0.59 Mil.
Market Cap (Today) was $0.00 Mil.
Total Liabilities was $14.32 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2.544 - 13.797)/3.254
=-3.4582

X2=Retained Earnings/Total Assets
=-46.312/3.254
=-14.2323

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-8.953 - -2.596)/3.254
=-1.9536

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.000/14.316
=0

X5=Revenue/Total Assets
=0.589/3.254
=0.181

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Adynxx has a Altman Z-Score of N/A indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Adynxx  (OTCPK:ADYX) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Adynxx Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Adynxx's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (Adynxx) Business Description

Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Executives
Gregory J. Flesher director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning officer: CHIEF MEDICAL OFFICER C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102